Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance

Published 16/08/2018, 06:14
Updated 16/08/2018, 06:20
© Reuters. FILE PHOTO: The Pfizer logo is seen at their world headquarters in New York

© Reuters. FILE PHOTO: The Pfizer logo is seen at their world headquarters in New York

FRANKFURT (Reuters) - Pfizer (N:PFE) has agreed to pay German biotech firm BioNTech up to $425 million (£334.33 million) in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach.

Privately-held BioNTech will receive $120 million upfront plus up to $305 million depending on certain development achievements as well as tiered royalties on futures sales in the double-digit percentage range, the two companies said in a statement on Thursday.

Mainz-based BioNTech, valued at $2.3 billion in a January financing round, is specialising in so-called messenger RNA (mRNA) molecules that instruct human cells to produce therapeutic proteins or to launch an immune response.

The emergent field has seen drugmakers such as AstraZeneca (L:AZN), Eli Lilly (N:LLY) and Sanofi (PA:SASY) partner up with biotech firms.

"mRNA vaccines offer a novel approach to code for any protein or multiple proteins, and the potential to manufacture higher potency flu vaccines more rapidly and at a lower cost than contemporary flu vaccines," said Kathrin Jansen, the head of Pfizer's vaccine research and development unit.

Flu jabs are currently produced from chicken eggs based on the previous flu season's viral strains. The alliance partners hope to offer a vaccine that can be quickly adjusted to the latest viral mutations, which can also be a major advantage in case of a pandemic threat from avian flu.

Pfizer will take over testing on humans and commercialisation of BioNTech's flu vaccines once the German firm, which is Europe's largest unlisted biotech firm by staff numbers, has completed the first clinical study.

Having raised $270 million from investors early this year, BioNTech is also developing personalised immunotherapies for cancer and is eyeing a future public listing.

The company competes in the race for mRNA therapies with groups such as Massachusetts-based Moderna Therapeutics, Belgium's eTheRNA and domestic rival CureVac.

CureVac's work on jabs to prevent malaria and influenza won more financial backing from its investor the Bill & Melinda Gates Foundation in a February agreement.

BioNTech, for its part, has previously attracted alliance partners including Roche's (S:ROG) Genentech, Eli Lilly, Sanofi, Genmab (CO:GEN) and Bayer Animal Health (DE:BAYGn).

As part of the upfront payment, Pfizer will acquire a "smaller" stake in the Germany company. Precise terms were not disclosed.

© Reuters. FILE PHOTO: The Pfizer logo is seen at their world headquarters in New York

Biotech investors Thomas and Andreas Struengmann, who sold their generic drugs business Hexal to Novartis (S:NOVN) in 2005, will remain majority shareholders in BioNTech.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.